secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001013762-23-005230
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics receives Nasdaq bid price deficiency notice; must regain compliance by Apr 15, 2024
--------------------------------------------------------------------------------

- Notice from Nasdaq: common stock bid price below $1.00 for 30 consecutive business days.
- Company has 180 days, until April 15, 2024, to regain compliance with Rule 5550(a)(2).
- If bid price closes at $1.00 or more for ten consecutive days, Nasdaq will confirm compliance.
- Company may consider a reverse stock split to cure deficiency; no assurance of regaining compliance.
- Trading of common stock (JSPR) and warrants (JSPRW) continues on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000101376223005230/0001013762-23-005230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000101376223005230/ea186965-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-005230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer